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Escherichia coli (E. coli) and Klebsiella pneumoniae (K. pneumoniae) are classi-
fied in the family Enterobacteriaceae. Species in these two genera are gram nega-
tive rods and frequently cause nosocomial and community-associated infections
such as urinary tract infections, wound infections, and bacteremia. As narrow and
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Purpose: Extended spectrum β-lactamases (ESBLs) are cephalosporinases that
confer resistance to a wide variety of oxyimino cephalosporins and create serious
therapeutic problems. In addition, the quinolone resistance qnr genes are becom-
ing increasingly prevalent in clinical isolates, some of which also produce ESBL.
This study was designed to evaluate the occurrence and genotypic distribution of
ESBL producing Escherichia coli (E. coli) and Klebsiella pneumoniae (K. pneu-
moniae) as well as the prevalence and distribution of qnr genes in ESBL-produc-
ing isolates in a tertiary care hospital in Korea. Materials and Methods: We
tested a total of 111 ESBL-producing isolates of E. coli and K. pneumoniae, which
were collected at Kyung Hee Medical Center from November 2006 to June 2008.
ESBL production was determined by the Clinical and Laboratory Standards Institute
(CLSI) ESBL confirmatory test. The cefotaxime and ceftazidime resistance of the
ESBL-producers were transferred to azide-resistant E. coli J53 by conjugation.
The presence and identity of ESBL and qnr genes were determined by polymerase
chain reaction (PCR) and nucleotide sequencing. Results: The prevalence of
ESBLs was 17.7% (297/1,680) of E. coli and 26.5% (240/904) of K. pneumoniae
in our hospital during the study periods. Of the 111 collected isolates, 69 isolates
were E. coli and 42 isolates were K. pneumoniae. The most prevalent ESBL
genotype was CTX-M15. Among the ESBL-producing isolates, 4 E. coli (5.8%)
and 17 K. pneumoniae (40.5%) contained qnr genes. qnrB4 was the most frequent
type in both E. coli and K. pneumoniae. Conclusion: CTX-M15 was the most
frequently encountered ESBL. In addition, a high prevalence of qnr genes among
ESBL-producing K. pneumoniae was identified in this study. 
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INTRODUCTIONextended-spectrum cephalosphorins are frequently used for
treatment of infections by these species, resistance rates to
these antimicrobial agents have also been increasing.
1
Extended-spectrum β-lactamase (ESBL) producers are
resistant to penicillins, narrow- and extended-spectrum
cephalosporins, and aztreonam. These organisms are also
frequently resistant to aminoglycosides, trimethoprim-
sulfamethoxasole (TMP-SMZ), and quinolones. Therefore,
the choice of antimicrobial agent to properly treat ESBL
producers requires accurate identification. The ESBLs were
first reported in 1983 and the prevalence and genotypes of
ESBL-producing isolates have been reported in Korea since
then.
2-7
The first plasmid-mediated quinolone resistance-con-
ferring gene (qnr) was reported in a K. pneumoniae clinical
isolate from the USA in 1998.
8 The qnr gene protects DNA
gyrase against the effect of the quinolone.
9 Recently, many
studies have reported that the qnr gene is frequently encoun-
tered in ESBL-producing isolates.
10-15
The distribution of ESBL genotypes has been found to
vary according to the antimicrobial agents used in each
hospital or local community.
16,17 However, the distribution
of genotypes of ESBL has not yet been reported in this
hospital. Therefore, this study was designed to assess the
prevalence and genotypes of ESBL-producing clinical
isolates of E. coli and K. pneumoniae in Kyung Hee Medi-
cal Center as well as to evaluate the prevalence and geno-
types of qnr genes in ESBL-producing isolates. 
Bacterial strains
Nonduplicate ESBL-producing clinical isolates of E. coli
and K. pneumoniae were randomly collected at Kyung Hee
Medical Center from November 2006 to June 2008. All isola-
tes were collected from inpatients. Conventional biochemi-
cal tests and MicroScan WalkAway 96 (Dade Behring, Sac-
ramento, CA, USA) were used for bacterial identification.
For optimization of the PCR technique, well-character-
ized ESBL and qnr-positive strains were used as positive
controls: K. pneumoniae SHV-12+,
12 Shigella sonnei (S.
sonnei) TEM-19+ (Korea Centers for Disease Control and
Prevention, unpublished results), K. pneumoniae CTX-
M3+,
12 and S. sonnei CTX-M14+ (Korea Centers for
Disease Control and Prevention, unpublished results) ;
Enterobacter cloacae (E. cloacae) qnrA+, Citrobacter
freundii qnrB+, and E. cloacae qnrS+.
13
ESBL confirmatory test
The phenotypic confirmatory test for ESBL production
was performed by the disk diffusion method according to




Antimicrobial susceptibilities were determined by agar
dilution methods according to the recommendations of the
CLSI.
18 The tested antibiotics were amikacin (Boryung,
Seoul, Korea), cefoxitin (Shinpoong, Seoul, Korea), cefe-
pime (Boryung, Seoul, Korea), ceftazidime (LG Life Sci-
ences, Seoul, Korea), cefotaxime (Handok, Seoul, Korea),
aztreonam (Bristol-Myers Squibb, Princeton, NJ, USA),
and ciprofloxacin (Bayer Vital GmbH, Berlin, Germany). 
β β-lactam resistance transfer assays
Conjugation experiments were carried out using the azide-
resistant recipient strain E. coli J53 according to the method
of Jacoby and Han.
19 Each clinical and recipient strain was
inoculated into brain heart infusion broth and incubated for
3 hours. 0.2 mL of donor culture solutions and 2.2 mL of
recipient culture solutions were mixed in a tube and incu-
bated at 37˚C for 1 hour. These mixed cultures were then
inoculated on MacConkey agar supplemented with cefta-
zidime or cefotaxime (8 µg/mL, respectively) and 100
µg/mL of sodium azide (Sigma chemical Co., St. Louis,
MO, USA). Transconjugants were selected after overnight
incubation at 35˚C in ambient air. To confirm transference
of resistance, transconjugants were subjected to the ESBL
confirmation test and polymerase chain reaction (PCR)
with primers listed in Table 1. 
Molecular analysis
The plasmid deoxyribonucleic acid (DNA) was prepared
using the Plasmid Purification Kit (SolGent Co., Daejeon,
Korea) according to the manufacturer’s recommendation.
PCR amplification of the genes of ESBL and qnr genes were
performed with primers listed in Table 1, as described previ-
ously.
10,17,20  PCR products were analyzed by electrophoresis in
a 2% agarose gel containing 0.5 µg/mL ethidium bromide at
120V for 40 min. The PCR products were purified with
Agencourt Ampure (Beckman Coulter, Brea, CA, USA) and
Biomek FX (Beckman Coulter, Brea, CA, USA) and sequ-
enced on a 3730xl DNA analyzer (PE Applied Biosystems,
Foster City, CA, USA). The nucleotide sequences were
analyzed with software available from the National Center
for Biotechnology Information BLAST service (http://
www.ncbi.nlm.nih.gov/BLAST).
Study sample
A total of 111 isolates, including 69 E. coli isolates and 42
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MATERIALS AND METHODS
RESULTSK. pneumoniae isolates, were collected from the Kyung
Hee Medical Center for analysis. These isolates were ob-
tained from urine (64 isolates), sputum (27 isolates), blood
(8 isolates), and other patient samples (12 isolates). 
During the study period, the overall incidence of ESBL-
producing isolates identified in the Kyung Hee Medical
Center was 17.7% (297/1,680) of E. coli and 26.5% (240/
904) of K. pneumoniae cases. 
Susceptibility testing
The resistance rates of E. coli and K. pneumoniae for amika-
cin, cefoxitin, cefepime, ceftazidime, cefotaxime, aztreo-
nam, and ciprofloxacin are shown Table 2. Isolates contain-
ing qnr genes were highly resistant to ciprofloxacin (MIC
≥ 16 µg/mL) except for two K. pneumoniae isolates that
were intermediately resistant (MIC 2 µg/mL). These isolates
encoded qnrB4 and qnrS1, respectively. 
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Table 1.Sequences of the Primers Used in This Study
Primers Target Primer sequence (5’-3’) Product size (bp) Position* Reference
SHV blaSHV GGTTATGCGTTATATTAATC 867 121 - 140 38
TTAGCGTTGCCAGTGCTC 971 - 988
TEM blaTEM ATAAAATTCTTGAAGACGAAA 1080 1 - 21 38
GACAGTTACCAATGCTTAATC 1061 - 1081
CTX-M1 blaCTX-M (CTX-M1 group) AGTTCACGCTGATGGCGACG 676 85 - 104 17
AACCCAGGAAGCAGGCAGTCC 741 - 761
CTX-M9 blaCTX-M (CTX-M9 group) GATTGACCGTATTGGGAGTTT 947 108 - 128 6
CGGCTGGGTAAAATAGGTCA 919 - 938
QnrA qnrA1- qnrA6 AGAGGATTTCTCACGCCAGG 580 30 - 49 10
TGCCAGGCACAGATCTTGAC 589 - 608
QnrB qnrB1- qnrB6 GGMATHGAAATTCGCCACTG
� 264 283 - 302 10
TTTGCYGYYCGCCAGTCGAA
� 526 - 545
QnrS qnrS1- qnrS2 GCAAGTTCATTGAACAGGGT 428 137 - 156 10
TCTAAACCGTCGAGTTCGGCG 543 - 563
*nucleotide numbering begins at the initiation codon.
�M = A or C; H = A or C or T; Y = C or T.
Table 2.Susceptibility of ESBL-Producing E. coliand K. pneumoniaeIsolates to 7 Antimicrobial Agents
Isolates (No)
MIC (µg/mL) %
50 90 Range S I R
E. coli (69)
Amikacin 16 32 ≤2 to ≥64 87.1 8.6 4.3
Cefoxitin 8 8 1 to ≥64 94.3 1.4 4.3
Cefepime ≥64 ≥64 ≤1 to ≥64 38.6 10.0 51.4
Ceftazidime ≥64 ≥64 ≤1 to ≥64 21.4 8.6 70.0
Cefotaxime ≥64 ≥64 ≤1 to ≥64 2.9 7.1 90.0
Aztreonam ≥64 ≥64 ≤1 to ≥64 2.8 8.6 88.6
Ciprofloxacin ≥16 ≥16 ≤0.25 to ≥16 11.4 1.4 87.2
K. pneumoniae (42)
Amikacin 16 ≥64 ≤2 to ≥64 59.5 7.1 33.3
Cefoxitin ≥64 ≥64 2 to ≥64 45.2 9.6 45.2
Cefepime 32 ≥64 4 to ≥64 42.9 0.0 57.1
Ceftazidime ≥64 ≥64 ≥64 0.0 9.5 90.5
Cefotaxime ≥64 ≥64 8 to ≥64 7.1 16.7 76.2
Aztreonam ≥64 ≥64 ≥64 0.0 2.4 97.6
Ciprofloxacin ≥16 ≥16 2 to ≥16 14.3 4.8 80.9
ESBL, extended-spectrum β-lactamase; E. coli, Escherichia coli; K. pneumoniae, Klebsiella pneumoniae; MIC, minimum inhibitory concentration; S, susceptible; 
I, intermediate; R, resistant.β β-lactam resistance transfer assays
Transconjugants were obtained for 20 strains (29.0%) of E.
coli and 24 strains (57.1%) of K. pneumoniae using E. coli
J53 Az
r as the recipient strain, and tested positive in an
ESBL confirmatory test and PCR test for blaSHV or blaCTX-M.
One transconjugant displayed different results compared
with the original isolate, which contained SHV5 and CTX-
M15 while the transconjugant contained only CTX-M.
Molecular analysis 
The distribution of the genotypes of ESBLs in this study is
reported in Table 3. The most common types of ESBLs
identified were CTX-M15 (n = 44, 63.8%) and CTX-M14
(n = 25, 36.2%) among E. coli isolates and CTX-M15 (n =
17, 40.5%) and SHV-12 (n = 12, 28.6%) among K. pneu-
moniae isolates. Genes encoding CTX-M57 (n = 6, 14.3%)
were detected in K. pneumoniae isolates. Genes encoding
TEM-type β-lactamases were detected in 22 of 69 E. coli
isolates and 4 of 42 K. pneumoniae isolates, but all of them
were the broad-spectrum TEM-1. 
Among the ESBL producers, 5.8% (4/69) of E. coli and
40.5% (17/42) of K. pneumoniae contained qnr genes.
Among the known qnr subtypes, only qnrB4 (n = 18,
85.7%) and qnrS1 (n = 3, 14.3%) were detected. The distri-
bution of ESBL types in qnr containing isolates is shown
in Table 4. 
Although β-lactam antimicrobial agents are frequently used
for the treatment of E. coli and K. pneumoniae infections,
ESBL-producing isolates are becoming increasingly com-
mon. ESBL-producing isolates are of particular concern
because these traits can be horizontally-transmitted to
other isolates by plasmids and often cause nosocomial
infections.
21 The prevalence and genotype of ESBLs from
clinical isolates vary according to the country and even
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DISCUSSION
Table 3.ESBL Genotypes of E. coliand K. pneumoniaeIsolates




CTX-M15 + TEM-1  12
CTX-M14 + TEM-1 5
CTX-M14 + CTX-M15  3
CTX-M14 + CTX-M15 + TEM-1 3
CTX-M14 + SHV-12  1
CTX-M15 + SHV-5 + TEM-1 1
CTX-M15 + SHV-5 1
CTX-M15 + SHV-12 1
SHV-12 4




CTX-M15 + TEM-1   2
CTX-M57 6
CTX-M14 1
CTX-M14 + TEM-1   1
CTX-M14 + CTX-M15 + TEM-1  1
CTX-M14 + SHV-12 1
CTX-M14 + SHV-2a 1
SHV-12 11
SHV-5 4
ESBL, extended-spectrum β-lactamase; E. coli, Escherichia coli; K. pneumoniae,
Klebsiella pneumoniae.
Table 4.Distribution of ESBL Genotypes of qnr Gene Positive Isolates
Isolates qnr gene Type of β-lactamase No. of isolates
E. coli qnrB4 CTX-M15 1
CTX-M14 + CTX-M15 + TEM-1 1
SHV-12 1
SHV-5 1
K. pneumoniae qnrB4 CTX-M15 3
CTX-M14 + SHV-12   1






ESBL, extended-spectrum β-lactamase; E. coli, Escherichia coli; K. pneumoniae, Klebsiella pneumoniae.hospital at which they are isolated from. For example, 3%
(0-25%) of Enterobacteriaceae isolates from the USA were
reported to be ESBL-producing strains
22,23 while 0.1% of E.
coli and 0.3% of K. pneumoniae isolates in Japan were
ESBLs.
24 Additionally, there have been several reports re-
garding the prevalence of ESBL-producing E. coli and K.
pneumoniae in Korea, and previous reports presented that
approximately 10 % of E. coli and 25-30% of K. pneumo-
niae isolates produced ESBLs.
5,6 ESBL-producing E. coli
and K. pneumoniae isolates from Kyung Hee Medical
Center were investigated, and among the 1,680 E. coli and
904 K. pneumoniae cases, a total of 297 E. coli isolates
(17.7%) and 240 K. pneumoniae isolates (26.5%) were
found to be ESBL-producing during the study periods.
These results are similar to the ESBL incidence previously
reported within Korea, although a slight increase in preval-
ence of ESBL-producing E. coli was detected. 
Regarding the prevalence of the genotype of ESBLs in
Korea, Pai
25 reported that TEM-12 ESBL-producing E.
coli and SHV-12 producing K. pneumoniae were the most
common genotypes in the late 1990s. More recently,
Hong, et al.
26 reported that TEM-52 was the most prevalent
in both E. coli and K. pneumoniae in 2001. In contrast,
Kim, et al.,
27 Rhoo, et al.,
28 and Kang, et al.
4 reported that
CTX-M was most frequently produced in E. coli in 2005.
Similarly, CTX-M14- and CTX-M15- producing E. coli
were the most frequently encountered genotypes in this
study. Surprisingly, TEM-52, the most frequently encoun-
tered genotype from previous reports, was not detected in
this study. In the case of K. pneumoniae, SHV-12 accounted
for 69% (27/39) of ESBLs in 1998
29 and 86% (31/36) of
ESBLs in 2006
28 in Korea. However, in this study, CTX-
M15 was the most prevalent (40.5%, 17/42), followed by
SHV-12 (28.6%, 12/42). CTX-M3 or 15 types in E. coli
and SHV-12 type in K. pneumoniae were predominant in
most parts of Korea, but CTX-M3 and CTX-M14 types
were most common in E. coli and K. pneumoniae, respec-
tively, in a hospital in Gyeonggi in 2005.
4 Our results were
of a similar distribution to other hospitals in the different
locations in Korea.
Interestingly, six isolates of K. pneumoniae expressed
CTX-M57. CTX-M57 was first identified from Salmo-
nella enterica in 2008.
30 CTX-M57 shares 99% amino acid
identity with CTX-M15 and differs from CTX-M15 by an
A80V substitution. Though CTX-M occurred in 1.7%
(9/520) of ESBLs in 2002,
2 its prevalence within ESBLs
increased to 4.3% (25/585) in 2005.
28 This increase in pre-
valence of CTX-M is likely because gene acquisition of
CTX-M or SHV is more effective than TEM in Enterobac-
teriaceae.
17 In order to test for transference of β-lactam resis-
tance, transconjugants were obtained from 29.0% (20/69)
of E. coli and 57.1% (24/42) of K. pneumoniae tested using
E. coli J53 Az
r as the recipients strain, and represented
positive results for the ESBL confirmatory test and tested
positive in SHV or CTX-M by PCR. However, one trans-
conjugant displayed different results compared with the
original strain, which contained SHV5 and CTX-M15 while
the transconjugant contained only CTX-M. This result
suggests that SHV and CTX-M were not present on the
same plasmid in the original isolate. There are several
reports of isolates which contain both SHV and CTX-M,
and these isolates express high resistance to not only cefta-
zidime but also ceftaxime. Therefore, a further investiga-
tion into whether SHV and CTX-M were present on same
plasmid is required.
Quinolone resistance of Enterobactericeae is usually
caused by various chromosomal mutations that alter the
target enzymes, such as DNA gyrase, type IV topoisome-
rase, or active efflux systems. However, since the first
plasmid-mediated quinolone resistance-conferring gene
(qnr) was discovered in a K. pneumoniae isolate from
USA, this gene has been reported worldwide,
15,31,32 and is
frequently encountered in ESBL-producing isolates.
10,12,14
Recently, there have been some reports regarding the dis-
tribution of the qnr gene in Korea. Kim, et al.
12 identified
44 isolates of ESBL-producing K. pneumoniae that tested
positive for the qnrB gene, and 2 of these also tested posi-
tive for the qnrS gene. Shin, et al.
33 reported that 5.6%
(8/143) of E. coli and 55.9% (33/59) of K. pneumoniae
isolates contained the qnrB gene among ciprofloxacin-
resistant isolates. In this study, 5.8% (4/69) of E. coli and
33.3% (14/42) of K. pneumoniae had the qnrB4 gene and
7.1% (3/42) of K. pneumoniae had the qnrS1 gene. These
results confirm previous reports regarding the high preval-
ence of the qnr gene, especially qnrB4, in K. pneumoniae.
Interestingly, only one study
13 has previously reported the
identification of qnrS1 in Korea, which was found in a
non-ESBL E. cloacae isolate. However, in this study, three
isolates of K. pneumoniae contained the qnrS1. This could
be an indication that the qnr gene has spread to several
Enterobacteriaceae species. Two isolates of qnr-containing
strains expressed intermediate susceptibility to ciprofloxa-
cin. Previous analyses have reported that despite the cases
that reported susceptibility to quinolone in the MIC test
according to the CLSI guidelines, some isolates contained
the qnr gene.
33-36 The qnr-positive strain have been asso-
ciated with only low-level resistance to fluoroquinolones
in transconjugants,
33 and most donor strains showed high
levels of quinolone resistance with additional chromosomal
mutations.
9 Therefore, the presence of qnr may be contri-
buted to the intensity and facilitation of quinolone resis-
tance.
9,33 In particular, because fluoroquinolones were
widely used in Korea,
37 the emergence and spread of qnr
genes would contribute to the rapid development and spread
Myeong Hee Kim, et al.
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33 Therefore, we considered
that early detection of qnr gene was very important for the
prevention of the development and spread of this resistance.
In summary, CTX-M15 was the most frequently encoun-
tered in E. coli and K. pneumoniae isolated in the Kyung
Hee Medical Center. In addition, new CTX-M57 was fre-
quently detected in K. pneumoniae. Finally, a high preval-
ence of qnr genes on ESBL-producing strains was detected.
β-lactam agents and quinolones should therefore be used
cautiously in these species, and continuously monitored for
resistance patterns. 
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